PROFILE · Innovative training network: Immunoprofile-directed stratification of patients with the autoimmune disorder thrombotic thrombocytopenic purpura
„Хоризонт 2020“ — Действия „Мария Склодовска-Кюри“
- Период
- 2015-10-01 → 2019-09-30
- Финансиране от ЕС
- 1 464 398 €
- Участници
- 9
- Схема
- MSCA-ITN-EID
Линиите свързват координатора с партньорите.
Накратко на български
Специфични маркери като антитела и Т-клетки при пациенти с автоимунното заболяване тромботична тромбоцитопенична пурпура се анализират, за да се създадат индивидуални профили. Това помага за по-точна диагностика, предвиждане на рецидиви и разработване на персонализирано лечение.
Кратко обяснение, генерирано от езиков модел по текста на CORDIS. Оригиналът е по-долу.
Резултати накратко
Innovative training network: Immunoprofile-directed stratification of patients with the autoimmune disorder thrombotic thrombocytopenic purpura
Problem The increasing prevalence of autoimmune disease represents a major challenge for the healthcare system in Europe. Current treatments are far from being optimal as virtually all patients receive the same, non-specific treatment. In the current PROFILE project, we study the autoimmune disorder acquired thrombotic thrombocytopenic purpura (aTTP). The unmet clinical needs are fine-tuned diagnostic tools and truly personalised treatment options. We want to identify how patients with aTTP match or differ from each other. Specific markers in each patient will be identified which will lead to a barcode profile. Patient stratification by barcode should allow better prediction of relapse. On top of that, treatment options will be identified and developed for each patient group. Impact to society The PROFILE project will result in improved diagnosis and treatment of patients suffering from aTTP. This will lead to an increased quality of life and a significant reduction in healthcare costs. Importantly, the strategy applied in this project to aTTP patients can easily be translated to many other autoimmune disease settings. Overall objectives Objective 1: To understand the role of specific markers (immunoprofiling markers: antibodies and T-cells) in the autoimmune disease aTTP Objective 2: To group patients with matching markers Objective 3: To link the markers with disease prognosis Objective 4: To develop novel treatment strategies To reach these objectives, the six early stage researchers (ESRs) working in the PROFILE project are receiving specialized training. They learn how to identify a clinical need, perform translational research, transfer technology and knowledge to the industry, manage intellectual property rights and act as competent managers. The scientific objectives and the high-level training and supervision of the ESRs is realised by the combination of highly skilled and specialized immunoprofiling experts from small and medium enterprises (Icosagen and Protobios, Estonia; Immudex, Denmark; Biokit, Spain; PharmaTarget, The Netherlands) as well as world-leading experts on acquired TTP from academia (KU Leuven, Belgium; Sanquin, The Netherlands; Assistance Publique-Hopitaux de Paris, France). Translational aspects are well covered by the inclusion of expert clinicians (Assistance Publique-Hospitaux de Paris, France) as well as representatives from patient groups (Stichting Zeldzame Bloedziekten, The Netherlands). Specific aspects of the training program are brought to the ESR during network wide events that are organised every 6 months. Importantly, these training sessions are open to all interested and are announced well in advance via our website (www.itn-profile.eu). Dissemination of results emanating from the PROFILE consortium to patients, clinicians and other groups of interest is ensured by the inclusion of the European Hematology Association (EHA) as a partner organisation.
Текст от CORDIS, на английски · Данни: CORDIS, © Европейски съюз
Цел на проекта
The PROFILE Innovative European Industrial Doctoral programme will develop improved tools for stratification of patients with the autoimmune disorder acquired thrombotic thrombocytopenic purpura (TTP). Patient stratification is needed in order to further develop personalized medicine approaches for human disorders. Therefore, a detailed understanding of the disease at the molecular level is needed. Furthermore, implementation of a robust set of novel biomarkers is essential for stratification of patients. Also, highly flexible platforms to rapidly develop novel therapeutics are crucial to further boost the field of personalized medicine. The research program is embedded in a unique translational training program, which emphasizes clinical needs as a driving force for development of novel, innovative diagnostics and therapeutics (for personalized medicine). There is intersectoral knowledge transfer between academia and companies at the European level as 6 different EU Member states are involved in the network either as beneficiary or partner organization. The PROFILE network will allow 6 early stage researchers to follow this unique translational training. They will be trained in the clinic to identify clinical needs, in academia where they will contribute to a scientifically ambitious project and in the non-academic sector where they will be trained in a novel technologies and commercializing bioassays endowing them with an unique PROFILE for further advancing personalized medicine in Europe.
Оригинален текст от CORDIS (на английски).
Участници
- KATHOLIEKE UNIVERSITEIT LEUVEN · LeuvenКоординаторБелгия
- ASSISTANCE PUBLIQUE HOPITAUX DE PARIS · ParisФранция
- BIOKIT S.A. · LLIÇA D´AMUNTИспания
- Dutch TTP patient organization · AMERSFOORTНидерландия
- EUROPEAN HEMATOLOGY ASSOCIATION · DEN HAAGНидерландия
- ICOSAGEN AS · TARTUЕстония
- Immudex ApsДания
- PROTOBIOS OU · TallinnЕстония
- Stichting Sanquin Bloedvoorziening · AmsterdamНидерландия
Връзки
- Виж в CORDIS
- DOI: 10.3030/675746
- http://web.archive.org/web/20200918164858/https://www.itn-profile.eu/
- https://ec.europa.eu/research/participants/documents/downloadPublic?documentIds=080166e5bde09fe6&appId=PPGMS
- https://ec.europa.eu/research/participants/documents/downloadPublic?documentIds=080166e5c7da196c&appId=PPGMS
- https://ec.europa.eu/research/participants/documents/downloadPublic?documentIds=080166e5c7da208d&appId=PPGMS
- https://ec.europa.eu/research/participants/documents/downloadPublic?documentIds=080166e5c7da2f2b&appId=PPGMS
- https://ec.europa.eu/research/participants/documents/downloadPublic?documentIds=080166e5c7da32ec&appId=PPGMS
- https://ec.europa.eu/research/participants/documents/downloadPublic?documentIds=080166e5ca913c41&appId=PPGMS
- https://www.ec.europa.eu/research/participants/documents/downloadPublic?documentIds=080166e5a79fb369&appId=PPGMS
- https://www.ec.europa.eu/research/participants/documents/downloadPublic?documentIds=080166e5a7aa74d9&appId=PPGMS
Данни: CORDIS, © Европейски съюз
